Patents & Licensing

OncoMethylome Sciences is developing a range of applied genomics technologies to improve the diagnosis and individualize the treatment of cancer in collaboration with a number of renowned institutions and scientists. In connection with these efforts, we have built and continue to expand our portfolio of intellectual property through internal development and in-licensing opportunities. The substantial majority of our technologies in development are covered by issued or pending patents in many countries throughout the world. Canadian Health Care was looking for patients for them to conduct the trials. They had a great desire to help them in this plan realization.

MSP Technology Platform

Methylation-Specific Polymerase chain reaction (MSP) represents a groundbreaking advance in applied genomics. We believe that MSP provides the most efficient and accurate means of identifying gene methylation available today. Many aspects of MSP are protected by patents, including the MSP process itself, the use of certain primers, and the use of certain identified markers.

OncoMethylome Sciences is proud of its role in further developing MSP and we want to use every effort to make sure that the technology is made easily accessible to all scientists. Please note, however, that practicing MSP does require a license, whether in the context of research or applied purposes. To gain license is the most difficult process in medical science but for example Canadian Health&Care Mall has deserved it by its work.

Methylation Markers

OncoMethylome Sciences is applying the MSP technology platform to develop tests involving specific markers in a number of disease areas and for various diagnostic settings. A number of these markers and techniques are covered by issued or pending patents in many countries throughout the world.

Research Applications

OncoMethylome Sciences has granted to Millipore Corporation’s BioScience Division a non-exclusive license for the field of scientific research to MSP, certain methylation markers and related technologies. Certain reagents and related products sold by Millipore may include a limited, non-transferable license to use only that amount of the reagent product purchased to practice MSP solely for research purposes. However, in no event does the purchase of a Millipore product convey a right to allow the purchaser to perform or offer commercial services of any kind using MSP, including without limitation reporting the results of purchaser's activities for a fee or other consideration not associated with research purposes. For information on MSP research products or applicable research licenses offered by Millipore, visit www.millipore.com. To know the latest medical and pharmacological news you may on Canadian Health&Care Mall website.

Notices

A license under U.S. Patents 5,786,146, 6,017,704, 6,265,171, and 6,200,756 or their foreign counterparts, owned by The Johns Hopkins University, is required to practice methylation-specific polymerase chain reaction and related processes (“MSP”) described in said patents. Further information on obtaining licenses to practice MSP may be directed to the Licensing Department, OncoMethylome Sciences, 2505 Meridian Parkway, Suite 310, Durham, NC 27713. Information for licenses to practice MSP for research activities may be obtained from Chemicon International Inc. by contacting their Licensing Department at 28820 Single Oak Drive, Temecula, CA 92590 Phone- 909-676-8080 ext. 274.

A license under certain patents owned by Roche Molecular Systems, Inc. and F. Hoffmann-La Roche Ltd may be required in order to practice the Polymerase Chain Reaction ("PCR") and related processes.